SCHEMBL1959791

SCHEMBL1959791

CC(C)(C)C#Cc1cc(N(C(=O)c2ccc(Cl)cc2Cl)C2CCOC2)c(C(=O)O)s1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CYP2E1 P05181 1/20 0.44
▸ NR1I2 O75469 2/20 0.41
▸ SLC6A2 P23975 1/20 0.33
▸ SLC6A4 P31645 1/20 0.33
▸ SLC6A3 Q01959 1/20 0.33
▸ NPC1 O15118 2/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ RAB9A P51151 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ TSHR P16473 1/20 0.32
▸ CASP1 P29466 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32
▸ CNR1 P21554 2/20 0.32
▸ CNR2 P34972 2/20 0.32
▸ CYP3A4 P08684 1/20 0.31
▸ CCR2 P41597 1/20 0.31
▸ HCRTR2 O43614 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1958425 0.95 CYP2E1 (0.47) CYP2E1NR1I2SLC6A2SLC6A4SLC6A3
SCHEMBL1963057 0.91 CYP2E1 (0.42) CYP2E1NR1I2SLC6A2SLC6A4SLC6A3
SCHEMBL1963185 0.90 NR1I2 (0.45) CYP2E1NR1I2SLC6A2SLC6A4SLC6A3
SCHEMBL1958434 0.89 NR1I2 (0.47) CYP2E1NR1I2SLC6A2SLC6A4SLC6A3
SCHEMBL1961765 0.88 NR1I2 (0.46) CYP2E1NR1I2SLC6A2SLC6A4SLC6A3
SCHEMBL1960237 0.88 NR1I2 (0.42) CYP2E1NR1I2SLC6A2SLC6A4SLC6A3
SCHEMBL1960239 0.88 NR1I2 (0.42) CYP2E1NR1I2SLC6A2SLC6A4SLC6A3
SCHEMBL670265 0.88 NR1I2 (0.44) CYP2E1NR1I2SLC6A2SLC6A4SLC6A3
SCHEMBL1961757 0.88 NR1I2 (0.46) CYP2E1NR1I2SLC6A2SLC6A4SLC6A3
SCHEMBL670264 0.88 NR1I2 (0.44) CYP2E1NR1I2SLC6A2SLC6A4SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130136719-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-05-30 — — US claimed
EP-2504329-A1 5-ALKYNYL-THIOPHENE-2-CARBOXYLIC ACID DERIVATIVES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS Vertex Pharmaceuticals Incorporated (US) 2012-10-03 — — EP claimed
WO-2011068715-A1 5-ALKYNYL-THIOPHENE-2-CARBOXYLIC ACID DERIVATIVES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-06-09 — — WO claimed
US-20130136719-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-05-30 — — US disclosed
US-20130136719-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-05-30 — — US disclosed
US-20130136719-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-05-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130136719-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS HAVCR2, GTF3C3, ZC3HAV1 CYP2E1 75/4885NR1I2 312/4885SLC6A2 2985/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback